期刊文献+

外科治疗非小细胞肺癌的多因素回归分析及临床意义

Multivariate regression analysis of the surgical treatment of non-small cell lung cancer and its clinical significance
下载PDF
导出
摘要 目的总结外科治疗非小细胞肺癌的多因素回归分析及临床意义。方法我院自2000年8月至2011年8月共手术治疗病例中获得201余例非小细胞肺癌病例的临床资料进行回顾性分析,主要分析外科治疗因素对预后的影响。结果非小细胞肺癌患者的外科治疗因素与术后复发、转移显著相关(P<0.05);是影响发生复发、转移后非小细胞肺癌患者生存时间的独立因素(P<0.01)。结论多因素回归分析对非小细胞肺癌外科治疗可以改善其预后;具有显著提高其远期疗效。 [ Objective ] Summary of the multivariate regression analysis of the surgical treatment of non-small cell lung cancer and clinical significance. [ Methods ] The clinical data of more than 201 eases of non-small cell lung cancer eases from August 2000 to August 2011, eases of surgical treatment were retrospectively analyzed, the main analysis of the factors on the prognosis of surgical treatment. [ Results ] Surgical treatment factors in patients with non-small eell lung cancer with postoperative recurrence, metastasis was significantly (P 〈0.05); affect recurrence after the transfer of the independent factors of survival time of patients with non-small cell lung cancer (P 〈0.01). [ Conclusion ] Multivariate logistic regression analysis can improve the prognosis; significant improve its longterm efficacy of surgical treatment of non-small cell lung cancer.
出处 《中国医学工程》 2012年第6期10-10,13,共2页 China Medical Engineering
关键词 多因素分析 外科治疗 非小细胞肺癌 临床意义 multivariate analysis surgical treatment non-small cell lung cancer clinical significance
  • 相关文献

参考文献6

二级参考文献91

  • 1杨光煜,李含志,彭汝霞,顾以茼.化疗-手术-化疗综合治疗N_2小细胞肺癌疗效分析[J].中国肿瘤临床,1996,23(4):277-278. 被引量:8
  • 2汪道峰,曾灿光,林勇斌,侯景辉,朱志华.凋亡相关基因在Ⅰ、Ⅱ期非小细胞肺癌组织中的表达及临床意义[J].癌症,2006,25(3):359-362. 被引量:7
  • 3张大为,毛友生,刘向阳,张汝刚.小细胞肺癌外科为主的综合治疗结果[J].中华肿瘤杂志,1996,18(5):372-375. 被引量:10
  • 4[34]Jacoulet P, Depierre A, Moro D, et al. Long-term survivors of small-cell lung cancer(SCLC): A French muticenter study. Grouper Oncologie de Langue Francaise[J]. Ann Oncol, 1997,8(10): 1009~1014
  • 5[35]Groen HJ, Fokkema E, Biesma B, et al. Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: Anoncross-resistant cshedule[J]. J Clin Oncol, 1999, 17(3): 927~932
  • 6[36]Sonpavde G, Ansari R, Walker P, et al. Phase Ⅱ study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer: Hoosier Oncology Group Tral[J]. Am J Clin, 2000, 23(1): 68~70
  • 7[37]Nakanishi Y, Takayama K, Takano K, et al. Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer[J]. Am J Clin Oncol, 1999,22(4):399~402
  • 8[38]Tucker MA, Murray N, Shaw EG, et al. Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre[J]. J Natl Cancer Inst, 1997,89(23): 1782~1788
  • 9[39]Johnson BE, Cortazar P, Chute JP. Second lung cancer in patients successfully treated for lung cancer [J]. Semin Oncol. 1997, 24(4): 492~499
  • 10[40]Karp DD. Lung cancer chemoprevention and mangement of carcinoma in situ[J]. Semin Oncol, 1997, 24(4): 402~410

共引文献121

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部